Biomarkers related to carotid intima-media thickness and plaques in long-term survivors of ischemic stroke by Waje-Andreassen, Ulrike et al.
ORIGINAL ARTICLE
Biomarkers Related to Carotid Intima-Media Thickness
and Plaques in Long-Term Survivors of Ischemic Stroke
Ulrike Waje-Andreassen1 & Halvor Naess1 & Lars Thomassen1,2 &
Tove Helene Maroy1 & Kibret Yimer Mazengia1 & Geir Egil Eide3,4 &
Christian Alexander Vedeler1,2
Received: 11 January 2015 /Revised: 28 March 2015 /Accepted: 28 April 2015 /Published online: 8 May 2015
# The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract Lifestyle risk factors, inflammation and genetics
play a role in the development of atherosclerosis.We therefore
studied Fc gamma receptor (FcγR) polymorphisms, interleu-
kin (IL)-10 polymorphisms and other biomarkers related to
carotid intima-media thickness (cIMT) in patients with ische-
mic stroke at a young age. Patients were evaluated 12 years
after stroke occurrence. Patients (n=232) 49 years of age or
younger with an index stroke between 1988 and 1997 were
retrospectively selected. Blood samples were taken at a first
follow-up 6 years after the stroke. At a second follow-up,
additional arterial events were registered for 140 patients,
new blood samples were taken, and measurements of cIMT
and blood pressure (BP) were performed. Unadjusted logistic
regression analysis showed that cIMT ≥1 mm was associated
with age, male gender, additional arterial events, BP, choles-
terol, sedimentation rate, haemoglobin, triglycerides, creati-
nine, glycolysed haemoglobin (HbA1c) and FcγRIIIB-NaII/
NaII. Adjusted backward stepwise logistic regression showed
significance for age (odds ratio (OR) 1.13, 95 % confidence
interval (CI) 1.04 to1.23, p=0.003), male gender (OR 4.07,
95 % CI 1.15 to 14.5, p=0.030), HbA1c (OR 6.65, 95 % CI
1.21 to 36.5, p=0.029) and FcγRIIIB-NaII/NaII (OR 3.94,
95 % CI 1.08 to 14.3, p=0.037). In this long-term follow-up
study of patients with ischemic stroke at a young age,
FcγRIIIB-NaII/NaII was identified as a possible contributing
factor for cIMT ≥1 mm together with known risk factors, such
as age, male gender, systolic BP, additional arterial events and
HbA1c.
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Introduction
Atherosclerosis is an inflammatory disease with both lifestyle
and genetic risk factors. Receptors for the Fc portion of im-
munoglobulin G (IgG), known as FcγRs, are the binding link
between humoral and cellular immunologic reactions. Endo-
thelial cells express FcγRs and pro-inflammatory mediators,
such as immune complexes and C-reactive protein, that can
activate FcγR-dependent pathways that lead to oxidative
burst, degranulation, phagocytosis, cytokine production and
antibody-dependent cell-mediated cytotoxicity (ADCC) [1].
The FcγRs are surface glycoproteins, encoded by eight genes
located on chromosome 1q21–23. Based on structural homol-
ogy and differences in affinity for IgG, this family is divided
into three subfamilies: FcγRI (CD64), FcγRII (CD32) and
FcγRIII (CD16). FcγR isoforms can be activating receptors
(FcRI, FcγRIIA and FcγRIII) or inhibitory receptors
(FcγRIIB) [1]. Two studies have demonstrated associations
between certain FcγRIIA polymorphisms and coronary artery
disease (CAD) and ischemic stroke [2, 3]. However, a study of
patients with myocardial infarction and patients with CAD,
documented by angiography, did not confirm this association
[4]. Protective effects have been reported for the FcγRIIA
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polymorphism and peripheral atherosclerosis [5], and an in-
verse relation has been found for FcγRIIIA and CAD [6].
Interleukin (IL)-10 is another important immune regulator
that may be important in the pathogenesis of atherosclerosis
[7]. Low levels of expression of IL-10 are associated with
atherosclerosis and cardiac and vascular dysfunction in mouse
models [8, 9], and in humans, reduced levels of IL-10 are
associated with carotid atherosclerosis and coronary disease
[10, 11]. IL-10 production varies due to single-nucleotide
polymorphisms (SNPs) in the promoter region of the IL-10
gene [12]. IL-10 SNPs have been identified at positions −1082
(A/G), −819 (C/T) and −592 (A/C) in Caucasians and form
the haplotypes ATA, ACC and GCC in six possible combina-
tions [13]. The genotype GCC/GCC is associated with high
production of IL-10; GCC/ACC and GCC/ATAwith medium
production; and ATA/ATA, ATA/ACC and ACC/ACC with
low production of IL-10 [14]. Although the IL-10 gene is also
localised on chromosome 1, the polymorphisms of IL-10 and
FcγR are not related. However, it has been shown that cross-
linking of FcγRs onmacrophages influence the IL-10 produc-
tion [15].
We have previously reported data from 232 patients who
had suffered acute arterial ischemic stroke at ages between 15
and 49 years and found a 10-fold higher mortality rate and a 5-
fold increased vascular morbidity rate among long-term sur-
vivors compared with controls [16]. After a mean observation
time of 12 years from the index stroke, individual maximum
carotid intima-media thickness (cIMT) values were ≥1.0 mm
in 76 % of 140 examined patients, based on 5944 wall-
segmental measurements [17].
In the present study, we analysed these retrospectively se-
lected young stroke patients with the following biomarkers:
C-reactive protein (CRP), homocysteine, cholesterol and tri-
glycerides, sedimentation rate (SR), haemoglobin (Hb),
glycolysed haemoglobin (HbA1c), creatinine, leukocytes,
thrombocytes, and FcγR polymorphisms, IL-10 polymor-
phisms and Chlamydia pneumoniae antibodies. For multivar-
iate analysis, we related these parameters and other relevant
clinical information, such as age, gender, blood pressure,
number of smoking years and additional arterial events other
than the index stroke to cIMT.
Methods
Patients and Study Design
We identified 232 patients of less than 50 years of age with
first-ever ischemic stroke between 1988 and 1997 from five
acute care hospitals in Hordaland County in western Norway
[16]. The mean age (standard deviation, SD) of the subjects
was 41.1 (±7.5) years at the time of the index stroke. Ischemic
stroke was defined according to the Baltimore Washington
Cooperative Young Stroke Study Criteria as neurological def-
icits lasting longer than 24 h or clinical transient ischemic
attacks (TIAs) in which cerebral computed tomography (CT)
or magnetic resonance imaging (MRI) showed acute arterial
cerebral infarction related to clinical findings [18]. About two
thirds of the patients had anterior circulation infarction, about
one third had posterior circulation infarction, and despite more
serious affection of patients with anterior circulation infarc-
tion, the short-term outcome at discharge was favourable with
modified Rankin score ≤2 in 80 % [19]. From 1988 to 1997,
patients were mainly treated by platelet inhibition or
anticoagulation. Thrombolysis and treatment with statins were
not usual at that time. Figure 1 shows the flow chart of the
study. The first follow-up was done from 1998 to 2001 after a
mean time of 5.7 years from the index stroke. Blood samples
were taken from 198 participating patients and frozen at
−80 °C. Four patients refused blood sampling. A second
follow-up was done from 2004 to 2005 after a mean time of
11.9 years from the index stroke. Until the second follow-up,
45 patients had died, mainly from cardiovascular disease [20].
Of the 187 survivors, 144 (77 %) participated in clinical ex-
aminations, and 140 patients were examined with cIMT mea-
surements by B-mode ultrasound [17]. Two patients refused
blood sampling but permitted the use of samples taken for
other control purposes within 1 month. The mean age at this
follow-up was 52.9 years (SD±8.1, range 28–65 years).
FcγR Polymorphisms
FcγR polymorphisms were analysed as previously described
[6]. In brief, leukocytes were isolated from peripheral venous
blood samples (EDTA blood). DNA was extracted with
QIAampTM Blood Kit (Qiagen GmbH, Hilden, Germany).
FcγR genotypes were determined by polymerase chain reac-
tion (PCR), and all PCR products were analysed by electro-
phoresis [6].
IL-10 Polymorphisms
DNAwas extracted from whole-blood samples and examined
for IL-10 polymorphisms at positions −1082 (G/A), −819
(T/C) and −592 (A/C) using PCR and gene sequencing as
previously described [21]. The IL-10 haplotypes were deter-
mined and grouped into combinations with high IL-10 expres-
sion, medium IL-10 expression and low IL-10 expression.
Carotid Artery Imaging
Right- and left-sided cIMT examination of near and far walls
of the distal common carotid artery (CCA), bifurcation (BIF)
and the proximal internal carotid artery (ICA) were performed
at four predefined angles. CCA, BIF and ICAvessel segments
were identified by using the tip of the flow divider as an
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internal landmark. Segments had a length of 10 mm, and the
mean value was measured. A total of 5944 segmental mean
IMT or plaque values were obtained. The maximum value of
48 possible individual cIMT measurements was used as out-
come variable. cIMT results were used to divide subjects into
two cIMTcategories: <1.0 and ≥1.0 mm. Our 140 patients had
a mean age of 53 years, the oldest patients were 65 years old at
that final clinical follow-up, and total maximum IMT of
1.0 mm was chosen as measure of dichotomisation due to
literature [22, 23]. Methods, results and patients’ characteris-
tics were previously described in detail [17].
Data Analysis
Biomarkers were compared between the groups with
cIMT <1 mm and cIMT ≥1 mm. Age, additional arterial
events, systolic and diastolic BP, number of smoking
years, SR, HbA1c, creatinine, Hb, leukocytes, thrombo-
cytes and triglycerides were used as results from the sec-
ond follow-up. CRP, homocysteine, total cholesterol, LDL
cholesterol and HDL cholesterol were used as results from
the first and second follow-up. Categorical variables were
analysed with 3×2 chi-square test and Fisher’s exact test,
and Wilcoxon–Mann–Whitney test was used for continu-
ous variables. Unadjusted logistic regression analysis of
the dichotomised cIMT was used to evaluate the potential
relationships with FcγR polymorphisms, IL-10 haplo-
types with ATA/ATA as reference variable and with
C. pneumoniae antibodies. p values were calculated from
the likelihood ratio test. Multiple logistic regression anal-
ysis was done using the dichotomised cIMT results as
outcome in a backward stepwise selection process
retaining variables significant at the 5 % level in the final
model. Multiple linear regression analysis was done using
continuous maximum cIMT results as outcome in a back-
ward stepwise selection process retaining variables signif-
icant at the 5 % level in the final model. The analysis was
performed using the Statistical Package for Social Sci-
ences (SPSS) 20. p values <0.05 were considered
significant.
Results
Immunological Parameters and cIMT
Table 1 shows FcγRIIIB polymorphisms associated with
cIMT ≥1 mm. Table 2 shows total cholesterol, LDL cho-
lesterol and homocysteine from the first follow-up associ-
ated with cIMT ≥1 mm, and further association with Hb,
HbA1c and creatinine from the second follow-up. Age,
gender, systolic and diastolic BP and additional arterial
events were also associated with cIMT ≥1 mm (Table 2).
We found a significant association between the FcγRIIIB
NAII/NAII polymorphism and cIMT ≥1 mm by using un-
adjusted logistic regression and adjusted backward step-
wise logistic regression analysis (Table 3). However, linear
regression analysis showed non-significant results for the
FcγRIIIB NAII/NAII polymorphism relation with contin-
uous cIMT. There was also a significant association be-
tween the IL-10 GCC/ACC polymorphisms and cIMT
≥1 mm, but this was not correlated with other polymor-
phisms associated with the degree of IL-10 production
(Table 1). Therefore, we did not follow up the IL-10 re-
sults by performing final backward stepwise logistic and
linear regression analysis. C. pneumoniae antibodies, sed-
imentation rate and C-reactive protein were not associated
with cIMT ≥1 mm.
nd=23 
n=198 
nd=22 
n=232 
n=144 
Inclusion 
Index stroke between  
1988-1997 
First follow-up 
1998-2001 
Second follow-up 
2004-2005 
nbs=194 
nu=140 nbs=138 
Fig. 1 Flow chart of 232 retrospectively included ischemic stroke
patients after the index stroke at age 17 to 49 years; n=number of
patients who were identified and participated in follow-ups, nd=
numbers of patients who died between inclusion and first follow-up and
between first and second follow-up, nbs=number of collected blood
samples. Four patients at first follow-up and two patients at second
follow-up refused blood sampling, but both patients from second
follow-up permitted the use of blood samples from other health
controls, done within 1 month; nu=number of patients with carotid
ultrasound measurements
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Non-immunological Parameters and cIMT
cIMT ≥1 mm was associated with total cholesterol, LDL cho-
lesterol and homocysteine at the first, but not at the second,
follow-up (Table 2). Haemoglobin, HbA1c and creatinine
were also associated with cIMT ≥1 mm as were age, male
gender, systolic and diastolic BP and additional arterial events
other than the index stroke. HbA1c was associated with cIMT
≥1 mm in addition to age and male gender after unadjusted
logistic regression and results after adjusted backward step-
wise logistic regression analysis (Table 3). Final linear regres-
sion analysis for continuous cIMT showed associations with
age, additional arterial events, systolic BP and HbA1c
(Table 4). Male gender was no longer associated with cIMT
in that analysis.
Discussion
This is the first clinical study of long-term survivors of ische-
mic stroke at a young age to evaluate follow-up blood samples
and carotid IMT measurements. The mean observation time
was nearly 12 years, and the cIMT measurements also includ-
ed plaques, as we measured at standardised sites in order to
perform a staging of the carotid artery wall disease.
We have studied immunological and non-immunological
risk factors for cIMTas parameters for carotid atherosclerosis.
Our results showed no association with C. pneumoniae anti-
bodies and cIMT. The association between C. pneumoniae
antibodies and cardiovascular disease is unclear [24]. Further-
more, we did not find any association with cIMT and sedi-
mentation rate or C-reactive protein. However, these
Table 1 Fc gamma receptor (FcγR) polymorphisms and interleukin (IL)-10 polymorphisms related to carotid intima-media thickness (cIMT) with
≥1 mm as outcome variable
Immunology
Variables Number
%
cIMT <1 mm
n=34
cIMT ≥1 mm
n=104
LR test
p value
Fc gamma receptor (FcγR) polymorphisms
FcγRIIA n=138 0.313
H/H 15.9 5 17
H/R 42.0 18 40
R/R 42.0 11 47
FcγRIIIB n=138 0.036
NaI/NaI 12.0 6 10
NaI/NaII 43.5 19 41
NaII/NaII 44.9 9 53*
FcγRIIIA n=137 0.362
V/V 12.4 2 15
V/F 40.9 15 41
F/F 46.7 17 47
Interleukin (IL)-10 polymorphisms
n=138 0.102
ATA/ATA 7.2 4 6
ATA/ACC 9.4 5 8
ACC/ACC 7.2 1 9
GCC/ACC 26.8 4 33*
GCC/ATA 23.2 10 22
GCC/GCC 26.1 10 26
IL-10 producing genotypes [14]
Low IL-10 production:
ATA/ATA, ATA/ACC and ACC/ACC
10 23 0.353
Medium IL-10 production: GCC/ACC and GCC/ATA 14 55 0.238
High IL-10 production:
GCC/GCC
10 26 0.655
n number, LR likelihood ratio test from logistic regression
*Significant p value, p≤0.05
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parameters are crude markers for the evaluation of specific
immune responses in the vascular wall.
We also studied the FcγR and IL10 genotypes as they have
been linked to atherosclerosis. The frequencies of the FcγR
and IL-10 genotypes among our patients were comparable to
272 healthy controls previously reported from western Nor-
way [25, 26].
We found a significant association between FcγRIIIB
NaII/NaII and cIMT ≥1 mm. However, linear regression anal-
ysis showed non-significant results for continuous maximum
cIMT values. Others have reported that soluble FcγRIIIA is
associated with maximum cIMT [27], that the FcγRIIIAVV-
genotype is inversely related to the extent of coronary artery
disease [6] and that the FcγRIIA R allele is associated with
impaired endothelial vasodilation in patients with hypercho-
lesterolemia [28].
The present study is the first to show a possible association
with the low-affinity FcγRIIIB receptor and atherosclerosis as
measured by cIMT ≥1 mm. FcγRIIIB, as well as FcγRIIA
and FcγRIIIA, activates immune functions such as phagocy-
tosis, ADCC and release of inflammatory mediators and su-
peroxide radicals [29]. FcγRIIIB is only present on
granulocytes, and the FcγRIIIB-NA2 allotype shows lower
levels of phagocytosis of IgG1 and IgG3 opsonised particles
Table 2 Other clinical chemistry and clinical biomarkers related to carotid intima-media thickness (cIMT) ≥1 mm as outcome variable
n of samples cIMT <1 mm
mean value
(±SD)
cIMT ≥1 mm
mean value
(±SD)
p value
Data from first follow-up, 6 years after the index stroke
Chlamydia pneumoniae antibodies 140 3 8 0.728
Homocysteine (μM) 139 12.8 (16.7) 11.4* (7.7) 0.011
CRP (mg/L) 134 2.1 (3.1) 2.5 (6.5) 0.344
Total cholesterol (mM) 139 5.5 (1.1) 6.1*(1.1) 0.007
LDL cholesterol (mM) 139 3.48 (0.9) 3.90* (1.0) 0.030
HDL cholesterol (mM) 139 1.33 (0.4) 1.29 (0.4) 0.778
Data from second follow-up, 12 years after the index stroke
CRP (mg/L) 139 2.6 (3.0) 3.7 (5.7) 0.344
Sedimentation rate (mm) 135 8.8 (6.3) 12.9 (10.1) 0.055
Homocysteine (μM) 132 11.8 (10.4) 12.4 (7.5) 0.098
Total cholesterol (mM) 139 5.37 (1.0) 5.47 (1.2) 0.590
LDL-cholesterol (mM) 138 3.41 (0.9) 3.54 (1.1) 0.543
HDL-cholesterol (mM) 140 1.64 (0.5) 1.51 (0.4) 0.331
Triglycerides (mM) 137 1.43 (0.6) 1.75 (0.8) 0.065
Haemoglobin (g/dL) 139 14.0 (1.1) 14.6* (1.3) 0.024
Glycolysed haemoglobin (%) 135 5.4 (0.7) 5.8* (0.9) <0.001
Creatinine (μM) 138 64.3 (13.6) 83.1* (70.7) <0.001
Leukocytes (109/L) 140 7.3 (2.2) 7.2 (1.9) 0.948
Thrombocytes (109/L) 138 268 (55.4) 262 (74.6) 0.221
Other variables at second follow-up
Age (years) 140 45.6 (9.9) 55.2* (5.8) <0.001
Gender * 0.001
Males (N) 10 68
Females (N) 24 38
Blood pressure (mmHg) 137
Systolic 131 (18.4) 143* (16.8) 0.001
Diastolic 84 (11.1) 90* (9.9) 0.002
n of smoking years 53 active and 54 ex-smokers 22.3 (10.0) 26.9 (10.2) 0.078
AAE 6 46* 0.008
3×2 chi-square test and Fisher’s exact test for categorical variables andWilcoxon–Mann–Whitney test for continuous variables were used for comparison
of data. Mean value (±SD)
n number, SD standard deviation, μM micromole, CRP C-reactive protein, LDL low density lipoprotein, HDL high density lipoprotein, AAE additional
arterial event other than the index stroke (recurrent ischemic stroke, angina pectoris, myocardial infarction, peripheral artery disease)
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than the NA1 allotype [30]. Our results therefore indicate that
reductions in effector functions such as phagocytosis and
ADCC may contribute to the development of atherosclerosis.
Such findings are supported by knockout studies of the inhib-
itory FcγRIIB which shows an increased plaque formation
[31]. In addition to myeloid cells, FcγRIIB is expressed on
B cells where it suppresses B cell signaling and regulates IgG
production [32]. Defects of FcγRIIB on B cell will therefore
increase the IgG production, which was showed in this mouse
model [31]. Our results indicate that similar mechanisms may
take place in humans, as the NA2 allotype is associated with
reduced phagocytosis of IgG1 and IgG3 [30].
Stimulation of activating FcγRs on macrophages has been
found to induce an anti-inflammatory immune response with
increased IL-10 production [15]. It has also been proposed
that elevated IgG with IL-10 acting downstream is driving
the plaque formation [31]. Others have reported that reduced
levels of IL-10 and low-producing IL-10 genotypes are asso-
ciated with increased cIMT [10, 33] and that low-producing
IL-10 genotypes are associated with coronary disease [11] and
ischemic stroke [34].
We have also studied the polymorphisms of IL-10 since
50–70 % of the variance in IL-10 levels is genetically deter-
mined [35]. However, we found no association between high-,
medium- or low-producing IL-10 genotypes and cIMT
≥1mm. Unfortunately, we had no access to serum IL-10 levels
in our patients. Although we could not find any genetic risk
factor with IL-10 and cIMT, this does not exclude the impor-
tance of this anti-inflammatory cytokine in the pathogenesis of
atherosclerosis. The major roles of IL-10 in terms of athero-
sclerosis include inhibition of macrophage activation, as well
as inhibition of matrix metalloproteinase, pro-inflammatory
cytokines and cyclooxygenase-2 expression in lipid-loaded
Table 3 Significant results of
unadjusted logistic regression and
adjusted backward stepwise
logistic regression analysis,
related to maximum carotid
intima-media thickness,
categorised as <1 and ≥1 mm in
140 patients, measured 12 years
after acute ischemic stroke
Unadjusted logistic regression Adjusted logistic regression
Variables OR (95 % CI) p values OR (95 % CI) p values
FcγRIIIB NaI/NaI 1.00
FcγRIIIB NaII/NaII 2.78 1.18, 6.52 0.019 3.94 1.08, 14.3 0.037
Cholesterol 1.62 1.12, 2.34 0.010 – – –
SR 1.06 1.01, 1.12 0.031 – – –
Hb 1.41 1.02, 1.95 0.036 – – –
HbA1c 3.35 1.27, 8.86 0.015 6.65 1.21, 36.5 0.029
Triglycerides 1.75 1.00, 3.07 0.049 – – –
Creatinine 1.05 1.02, 1.08 0.001 – – –
Age 1.17 1.10, 1.25 <0.001 1.13 1.04, 1.23 0.003
Male gender 4.30 1.86, 9.93 0.001 4.07 1.15, 14.5 0.030
Systolic BP 1.05 1.02, 1.08 0.002 – – –
Diastolic BP 1.06 1.01, 1.10 0.008 – – –
AAE 3.64 1.39, 9.53 0.009 – – –
Unadjusted univariate logistic regression analysis was performed for all blood samples from the first and second
follow-up: FcγR polymorphisms, IL-10 polymorphisms, Chlamydia pneumoniae antibodies, homocysteine, C-
reactive protein, total cholesterol, LDL cholesterol, HDL cholesterol, SR, triglycerides, Hb, HbA1c, creatinine,
leukocytes and thrombocytes and for clinical variables, such as age, gender, systolic BP, diastolic BP and AAE.
Only significant found variables are listed and used in the adjusted backward stepwise logistic regression analysis
OR odds ratio, CI confidence interval, FcγR Fc gamma receptor polymorphism, SR sedimentation rate, Hb
haemoglobin, HbA1c glycolysed haemoglobin, BP blood pressure, AAE additional arterial events (recurrent
stroke and/or angina pectoris and/or myocardial infarction and/or peripheral artery disease) other than the index
stroke
Table 4 Final results of linear regression analysis, related to maximum
carotid intima-media thickness (cIMT), measured in 140 patients 12 years
after acute ischemic stroke
b Standard error (SE) p values
Age 0.25 0.007 0.002
Systolic BP 0.18 0.003 0.029
AAE 0.20 0.111 0.019
HbA1c 0.18 0.061 0.028
Linear regression analysis was performed with Fc gamma receptor IIIB
NaII/NaII polymorphism, total cholesterol, sedimentation rate,
haemoglobin, HbA1c, triglycerides, creatinine, age, gender, systolic BP
and AAE. Gender was non-significant in the final results (b=0.13, SE=
0.1, p=0.80)
b estimated regression coefficient, BP blood pressure, AAE additional
arterial event other than the index stroke, such as recurrent ischemic
stroke, angina pectoris, myocardial infarction and peripheral artery dis-
ease, HbA1c glycolysed haemoglobin
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and activated macrophage foam cells. Furthermore, another
important role of IL-10 in atherosclerosis is its ability to alter
lipid metabolism in macrophages [36]. Of the non-
immunological parameters, we found that cholesterol, triglyc-
erides, blood pressure and cardiovascular events were risk
factors in the unadjusted logistic regression analysis but not
in the adjusted logistic regression analysis. However, these are
known risk factors for subclinical carotid atherosclerosis [37,
38] At the first follow-up, statins were only used by 30
(15.5 %) of 194 patients with registered medication, and at
the second follow-up, statins were used by 55 (38.2 %) of 144
patients [16]. The increasing use of statins probably explains
why total cholesterol/homocysteine/and LDL-cholesterol
levels were associated with cIMT at the first follow-up but
not at the second follow-up.
We found that HbA1c, SR, haemoglobin and creatinine
were risk factors in the unadjusted logistic regression analysis,
but only HbA1c showed significance in the final adjusted
logistic and linear regression analysis. Elevated blood glucose
is a known risk factor for endothelial dysfunction and early
atherosclerosis [39], and the high percentage of carotid artery
atherosclerosis observed in our patients is in agreement with
this. Furthermore, we found that increased age and male gen-
der are correlated with increased cIMT as has been shown in
large population studies [37, 40]. Surprisingly, male gender
disappeared as significant result in the linear regression anal-
ysis, and other risk factors for increased cIMT and atheroscle-
rosis, such as systolic BP and additional arterial events, be-
came significant. Probably, the number of patients played a
role for the varying results by the different methods of regres-
sion analysis.
The strength of our study is that we have a very well
characterised patient population and clinically related immu-
nological and non-immunological parameters were available
for analysis. The frequencies of FcγR and IL-10 polymor-
phisms in our patients are similar to those observed in popu-
lation studies performed from the same area [25, 26]. We have
measurements of the various blood samples both at first and at
second follow-up. In addition, we did meticulous studies to
measure cIMT and plaques.
The weakness of our study is that patients were included
retrospectively and selection was affected by death and a 23%
dropout rate of long-term survivors. The 23 % dropout rate at
our last clinical follow-up, without any missing data
concerning the dead-alive status, is, however, comparable to
that of other clinical studies with follow-ups after 10 years
[41].
Differences occurred after logistic and linear regression
analysis concerning significancies related to cIMT in this
study. However, age and HbA1c were in both analyses related
to cIMT, and these parameters are well-known risk factors for
increased cIMT and atherosclerosis. Male gender and in-
creased BP are also well-known risk factors for atherosclerosis
and additional arterial events, even if the results by the two
types of regression analysis were slightly different. A new
finding in this study is that FcγRIIIB-NAII/NAII appeared
as a significant factor for increased cIMT ≥1 mm. However,
further prospective studies with higher sample sizes are nec-
essary to confirm these results.
In conclusion, we found that in patients with ischemic
stroke at a young age, FcγRIIIB-NAII/NAII may be a con-
tributing factor for increased cIMT together with known risk
factors, such as age, male gender, systolic BP and increased
HbA1c.
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